Evidence map›Paper›PMID 29194406›Full record

ArticleInternational journal of molecular sciences2017

Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.

Jou-Ku Chung, Luying Pan, Kathleen Palmieri, Amir S Youssef, Thomas G McCauley

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Mucopolysaccharidoses and the blood-brain barrier.Fluids and barriers of the CNS · 2022
    Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jou-Ku ChungNonclinical Development, Research and Discovery, Shire, 300 Shire Way, Lexington, MA 02421, USA. joukuc@gmail.com.
Luying PanNonclinical Development, Research and Discovery, Shire, 300 Shire Way, Lexington, MA 02421, USA. lpan@shire.com.
Kathleen PalmieriNonclinical Development, Research and Discovery, Shire, 300 Shire Way, Lexington, MA 02421, USA. kzpalmieri@shire.com.
Amir S YoussefKinderPharm/PKPD Bioscience Inc., 100 Arrandale Blvd #101, Exton, PA 19341, USA. ayoussef@kinderpharm.com.
Thomas G McCauleyNonclinical Development, Research and Discovery, Shire, 300 Shire Way, Lexington, MA 02421, USA. tmccauley000@gmail.com.
Takeda (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucopolysaccharidosis III type A (MPS IIIA; Sanfilippo syndrome), a genetic lysosomal disorder causing a deficiency of heparan N-sulfatase (HNS), leads to progressive cognitive decline from an early age. An effective enzyme replacement therapy (ERT) for MPS IIIA requires central nervous system (CNS) biodistribution. Recombinant human heparan

Indexed as

Administration, IntravenousAnimalsCentral Nervous SystemDisease Models, AnimalHumansInjections, SpinalMacaca fascicularisMaleMucopolysaccharidosis IIIRecombinant ProteinsSulfatasesTissue Distributionheparan sulfate sulfataseRecombinant ProteinsSulfatasescerebral spinal fluidenzyme replacement therapyintrathecal administrationlysosomal disordermucopolysaccharidosis III type Apharmacokineticspositron emission tomographyrecombinant human heparan N-sulfataseSanfilippo syndrome

Identifiers

PMID29194406
PMCPMC5751197
OpenAlexW2774440478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.